• Partnership to Identify Therapeutic Oncology Leads
    Dr Neil Butt

News & Views

Partnership to Identify Therapeutic Oncology Leads

Korean –based LG Chem Ltd and IONTAS, have signed a collaboration agreement for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers. IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem and to further prove the biological activity of the antibodies.

Dr Neil Butt, CBO of IONTAS said: “This new agreement marks IONTAS’ expansion into the Asian market and we are delighted to have been selected by LG Chem, Ltd, after a rigorous diligence process. The application of our proprietary technologies will assist LG Chem Ltd in expanding its current therapeutic pipeline by generating leads against pre-defined specifications agreed at the project outset.”

Dr Myung Jin Kim, Executive Vice President / R&D Leader, Life Sciences R&D of LG Chem said: “IONTAS was selected because of its robust track record and technical know-how. We feel confident this collaboration will result in a strong panel of therapeutic leads which will help develop our oncology pipeline.”


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

View all events